爾康製藥(300267.SZ):“磺胺甲噁唑”、“氫氧化鋁”原料藥通過CDE審批
格隆匯6月12日丨爾康製藥(300267.SZ)公佈,近日,公司從國家藥品監督管理局藥品審評中心(CDE)“原料藥、藥用輔料和藥包材登記信息公示”平台查詢獲悉,全資子公司湖南湘易康製藥有限公司(“湘易康”)提交的“磺胺甲噁唑”、“氫氧化鋁”原料藥(受理號:CYHT1600556、CYHT1600543)通過了CDE審批。
磺胺甲噁唑,磺胺類藥,主要用於治療敏感菌引起的尿路感染、呼吸系統感染、腸道感染、膽道感染及局部軟組織或創面感染等;氫氧化鋁,弱鹼性化合物,主要用於治療胃酸過多,胃及十二指腸潰瘍、反流性食管炎及上消化道出血、高磷酸鹽血癥。
“磺胺甲噁唑”、“氫氧化鋁”原料藥通過CDE審批,有利於公司加快原料藥產業佈局,進一步豐富公司原料藥品種,完善原料藥產品結構,為公司構建“原輔料+製劑一體化”商業生態提供更多支持。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.